Question: Cuprimine and Syprine are therapeutics approved by the USFDA to treat which disease?
Answer: The cited reference notes “Cuprimine and Syprine are therapeutics approved by the USFDA to treat copper overload in Wilson Disease (a genetic defect in copper transport) by chelation and accelerated excretion of internally-deposited copper. These oral therapeutics are based on the respective active ingredients D-penicillamine (DPA) and N,N -bis (2-aminoethyl) -1,2-ethanediamine dihydrochloride (Trien). Cuprimine is considered the primary treatment, although physicians are increasingly turning to Syprine as a first-line therapy.” (Levitskaia TG et al. Evaluation of cupramine and syprine form decorporation of radioisotopes of cesium, cobalt, iridium and strontium. 2011 Health Phys 101(2):118-127)